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 CD8  T lymphocytes (CD8-TLs) play a critical 
role in control of HIV and simian immunodefi -
ciency virus (SIV) infection. There is a strong 
temporal association between the onset of the 
initial HIV/SIV-specifi c CD8-TL response and 
the decline of peak viremia to the set point, 
which is maintained into the chronic phase ( 1 ). 
In addition, experimental in vivo depletion of 
CD8  cells in SIV-infected rhesus macaques 
results in a dramatic rise in viremia ( 2 ,  3 ), includ-
ing in animals that spontaneously control SIV 
replication (elite controllers) ( 4 ). Finally, there is 
a close correlation between certain MHC class I 
(MHC-I) alleles and control of viral replication, 
both in HIV-infected humans and SIV-infected 
macaques ( 5 – 8 ). This correlation implies that cer-
tain CD8-TL responses are better than others 
at controlling virus replication. It is, therefore, 
important to understand the entire AIDS virus –
 specifi c CD8-TL response, particularly in elite 
controllers, which might represent the rare in-
stances of eff ective CD8-TL responses. 
 CD8-TLs recognize virus-infected cells by 
engaging complexes of virally derived peptides 
and MHC-I molecules. The obvious and best-
studied source of these peptides is previously 
described viral proteins. The SIV genome con-
tains nine described open reading frames (ORFs), 
 gag ,  pol ,  vif ,  vpx ,  vpr ,  tat ,  rev ,  nef , and  env , encoding 
15 mature proteins. However, an understudied 
and potentially important source of such pep-
tides is defective ribosomal products (DRiPs) ( 9 ). 
Transcription and translation are highly error-
prone processes. Evidence suggests that such de-
fective products are rapidly degraded, and the 
resulting peptide fragments presented at the cell 
surface bound to MHC-I molecules ( 10 ,  11 ). 
 Peptides derived from translation of alternate 
reading frames (ARFs; henceforth called cryptic 
epitopes) are a potentially important class of 
DRiPs. Immune responses directed against cryp-
tic epitopes have been detected in several infec-
tions, including influenza virus ( 12 ), murine 
AIDS ( 13 ), and, importantly, HIV ( 14 ). Cardinaud 
et al. ( 14 ) used mice that express human MHC-I 
molecules to demonstrate the immunogenicity 
of predicted cryptic peptides. They also detected 
CD8-TL responses directed against these  peptides 
in HIV-infected patients. Although these experi-
ments elegantly demonstrated the existence of 
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 Cryptic major histocompatibility complex class I epitopes have been detected in several 
pathogens, but their importance in the immune response to AIDS viruses remains unknown. 
Here, we show that  Mamu-B*17  simian immunodefi ciency virus (SIV)mac239-infected 
rhesus macaques that spontaneously controlled viral replication consistently made strong 
CD8  T lymphocyte (CD8-TL) responses against a cryptic epitope, RHLAFKCLW (cRW9). 
Importantly, cRW9-specifi c CD8-TL selected for viral variation in vivo and effectively 
suppressed SIV replication in vitro, suggesting that they might play a key role in the SIV-
specifi c response. The discovery of an immunodominant CD8-TL response in elite controller 
macaques against a cryptic epitope suggests that the AIDS virus – specifi c cellular immune 
response is likely far more complex than is generally assumed. 
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epitopes encoded by ARFs in the SIVmac239 genome. We 
scanned all reading frames of the SIVmac239 genome not 
known to encode proteins. Using epitope prediction software 
( 16 ), we identifi ed a single peptide, cRW9, predicted to tightly 
bind (IC 50   50 nM) the Mamu-B*17 molecule. cRW9 is 
located in the 2 reading frame relative to the ORF encoding 
the envelope protein ( Fig. 1 ). It is located in the same ORF 
that encodes exon 1 of the Rev protein but is downstream of 
the only known splice donor site and so is not predicted to be 
translated under  “ normal ” biological circumstances. 
 CD8-TLs from SIV-infected macaques targeted cRW9 
 cRW9 was predicted to bind the Mamu-B*17 molecule with 
high enough affi  nity to be immunogenic, so we next used 
IFN-  ELISPOT to determine if any of our MHC-I – defi ned 
SIV-infected macaques made detectable cRW9-specifi c  immune 
responses. To our surprise, we found responses in several 
(13 of 20)  Mamu-B*17  macaques in the chronic phase of 
SIV infection, including two elite controllers, animals r95071 
and r98016 ( Fig. 2 a ). Responses just below the threshold 
of positivity were detected in two additional macaques. 
Response to the cRW9 peptide was not detected in SIV-naive 
 Mamu-B*17  macaques but was detected in one of fi ve SIV-
infected  Mamu-B*17  −  animals (r95003) ( Fig. 2 a ). This ani-
mal also made a response to another Mamu-B*17 – restricted 
epitope, Vif 65-73 HW8 (not depicted). Furthermore, virus from 
this animal harbored mutations in Vif 65-73 HW8 consistent with 
escape from this response ( 17 ). These data indicate that this 
animal likely expresses an unknown MHC-I allele that presents 
epitopes also bound by Mamu-B*17. We next measured 
responses in four animals, including the two elite controllers, 
against other known SIV-derived CD8-TL epitopes to assess 
the relative contribution of the cRW9-specifi c cells to the 
SIV-specifi c immune response ( Fig. 2 b ). The cRW9 re-
sponse comprised a substantial portion of the total SIV-
specifi c CD8-TL response, as measured against responses 
HIV-derived cryptic epitope-specifi c CD8-TLs, the importance 
of these responses in HIV-infected humans or SIV-infected 
macaques has not yet been addressed. 
 Previously, we demonstrated that the MHC-I allele  Mamu-
B*17 was associated with control of SIVmac239 replication 
and was overrepresented in a cohort of elite controllers ( 8 ). Here, 
we show that  Mamu-B*17  macaques mounted strong, chronic 
phase responses against a cryptic epitope, RHLAFKCLW 
(cRW9). This epitope lies in the 2 reading frame relative 
to the  env ORF, within the intron between the 5  and 3   rev 
exons. CD8-TLs recognizing this epitope were consistently 
detected in  Mamu-B*17  macaques and represented the 
immunodominant chronic phase response in one elite controller. 
cRW9-specifi c CD8-TLs also selected for viral variation 
in vivo. This mutation was synonymous in the overlapping 
 Env ORF but changed the C-terminal tryptophan anchor resi-
due, which is essential for binding of the peptide to the Mamu-
B*17 molecule ( 15 ). In addition, cRW9-specifi c CD8-TLs 
eff ectively suppressed virus replication in vitro. Collectively, 
these data suggest both that translation of the ARF that encodes 
cRW9 is a regular event in SIV infection and that immune re-
sponses against cryptic epitopes may be important components 
of the total SIV-specifi c repertoire in some individuals. 
 RESULTS AND DISCUSSION 
 SIVmac239 encodes a cryptic epitope predicted 
to bind to Mamu-B*17 
 The majority (9 of 13 in our cohort) of Indian rhesus macaques 
that control replication of the highly pathogenic simian AIDS 
virus SIVmac239 are  Mamu-B*17  ( 8 ). Reasoning that this 
association was due to eff ective CD8-TLs directed at Mamu-
B*17 – restricted epitopes, we sought to characterize the entire 
repertoire of SIV-specifi c Mamu-B*17 – restricted responses. 
Mamu-B*17 – restricted CD8-TL responses against epitopes 
derived from the 15 SIV proteins have been described ( 15 ). 
Therefore, in this study we searched for Mamu-B*17 – restricted 
 Figure 1.  Location of cRW9 in the SIVmac239 genome. The cRW9 epitope (enclosed in box) is located in the same reading frame (frame 3 in this 
image) as exon 1 of the  rev ORF but downstream of the only known splice donor site (indicated by an arrow). 
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molecules. In agreement with the ELISPOT data, the cRW9 
response was the highest frequency chronic phase CD8-TL 
response in this animal, comprising 41% of the total detect-
able SIV-directed CD8-TL response ( Fig. 2 d ). 
 Viral sequence evolution in cRW9 
 Because the cRW9-specifi c response was a consistent and 
often strong response, we wished to determine whether this 
response could select for viral variants in vivo. Viral escape 
from specifi c CD8-TL responses is a hallmark of AIDS virus 
infection ( 17 ,  18 ). If cryptic epitope-specifi c CD8-TLs exert 
appreciable selective pressure on the virus, escape variants 
should be selected for in vivo. Thus far, to our knowledge, 
viral escape from cryptic epitope-specifi c immune responses 
has not been documented. To examine this, we isolated 
restricted by the other MHC-I alleles expressed by these ani-
mals and known to present SIV epitopes. In animal r95071, 
the dominant SIV-specifi c response was against cRW9. 
Interestingly, this animal has maintained virus loads of   1,000 
viral RNA (vRNA) copies/ml plasma or less for most of its 
SIV infection history. 
 To determine the overall frequency of the cRW9-spe-
cifi c response, we made a tetramer of the Mamu-B*17 mole-
cule folded with the cRW9 peptide and again tested animals 
r98016 and r95071 ( Fig. 2 c ). The response was detected in 
both animals but was very strong in r95071. Because animal 
r95071 expresses two MHC-I molecules known to bind 
SIVmac239 epitopes, Mamu-A*02 and Mamu-B*17, we 
used tetramers to measure the frequency of the cRW9 re-
sponse relative to that of other responses restricted by these 
 Figure 2.  Magnitude of the cRW9-specifi c response in four animals. (a) IFN-  ELISPOT to determine if SIV-infected macaques (Mamu-B*17  or 
Mamu-B*17    ) or SIV-naive animals make cRW9-specifi c responses. Responses are measured as spot-forming cells (SFC) per million PBMCs. The mean 
number of spots of the negative control wells was subtracted from each well. Responses were considered positive if the number of spots (per million 
PBMCs) was   50 (represented by a vertical bar). Error bars represent the mean   the SE for each measurement. (b) IFN-  ELISPOT to test four animals in 
the chronic phase of SIV infection for responses to known SIV epitopes restricted by MHC-I alleles expressed by each animal. For each animal, a gray bar 
indicates the cRW9 response, while all others are black. On the x axis are the epitopes tested and their restricting alleles. (c) Elite controllers r95071 and 
r98016 were also tested for response frequency using tetramers of the Mamu-B*17 molecule loaded with the cRW9 peptide. Tetramer  populations are 
expressed as percentages of CD3  lymphocytes. (d) Animal r95071 was also tested for responses to epitopes restricted by the MHC-I molecules Mamu 
A*02 and Mamu-B*17. Percentages in the pie chart represent the frequency of each response (by tetramer) relative to other measured responses. 
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We analyzed   600 bp surrounding the ARF-encoding cRW9 
in 5 animals (shown in  Fig. 3 a ). The analyzed region encom-
passes most of  tat exon 1,  rev exon 1, and the region encoding 
the fi rst 100 amino acids of the envelope protein. We found 
evidence for selection in the regions encoding the envelope 
protein (P   0.001) and the cRW9 epitope (P 	 0.001), but 
not in the regions encoding Tat, Rev, or in the rest of the 
ARF that encodes cRW9 ( Fig. 3 c ). 
 Positive selection in the cRW9 epitope, resulting in abro-
gation of peptide binding, indicates that SIV evolves to evade 
the cRW9-specifi c response. However, viral escape from any 
CD8-TL response should result in a reduction in the ability of 
CD8-TLs to recognize cells presenting the variant peptide. 
To test this possibility, we used IFN-  ELISPOT with PBMCs 
from animal r95071 to determine whether cRW9-specifi c 
CD8-TLs could recognize variant peptides using a series of 
peptide dilutions. The variant peptide did not stimulate IFN-  
secretion, even at the highest concentration ( Fig. 4 a ). Com-
plete loss of recognition even at high peptide concentrations 
suggests that escape is complete in this novel epitope. 
 Next, we wished to determine whether the T6913C 
mutation was associated with decay in the frequency of the 
cRW9-specifi c response in vivo. To test this, we used tetramers 
to stain PBMCs from animals r98015 and r97044 at various 
time points after SIV infection. The frequency of the cRW9-
specifi c CD8-TL response dropped considerably after fi xation 
of the mutation in the cRW9 epitope (Fig. 4 b). These data 
provide further evidence that the T6913C mutation is an 
eff ective escape mutation. 
 Finally, we tested whether CD8-TLs could recognize cells 
infected with a virus harboring the escape variant of the 
cRW9 epitope. We used site-directed mutagenesis to gener-
ate a virus (SIV-T6913C) with the T6913C mutation. We 
infected target cells derived from SIV-naive macaques that 
were either  Mamu-B*17  or  Mamu-B*17    using magneto-
fection ( 19 ). 20 – 30% of the target cells were infected after 
24 h with either the wild-type SIVmac239 or the SIV-T6913C 
escape mutant virus (not depicted). Using intracellular cyto-
kine staining (ICS), we found that a cRW9-specifi c CD8-TL 
line recognized the wild-type – infected cells but did not rec-
ognize the SIV-T6913C – infected cells (Fig. 4 c). Collectively, 
these results indicate that cRW9-specifi c CD8-TLs selected 
for escape in vivo, drastically reducing epitope recognition and 
without changing the primary ORF. 
 Collectively, our escape data provide evidence that cRW9 
is encoded by a DRiP. Escape from the cRW9 response always 
involved changing the tryptophan anchor residue to an argi-
nine, leading to a near complete loss of recognition without 
diminishing the replicative capacity of the virus (unpublished 
data). Interestingly, escape from all other known Mamu-B*17 –
 restricted responses involves changes in residues other than the 
tryptophan anchor, and these  “ escape variant ” peptides are of-
ten recognized in cytokine secretion assays (unpublished data). 
It is possible that epitopes contained in bona fi de proteins can-
not escape by mutating the tryptophan anchor because, in func-
tional proteins, tryptophan often represents a residue critical for 
vRNA from the plasma of SIV-infected animals and sequenced 
the region encoding cRW9. SIV derived from 5 of 20 (19 
 Mamu-B*17  and 1  Mamu-B*17  −  [r95003]) animals sequenced 
at time of death contained an identical mutation, T6913C. 
This mutation is synonymous in the  env ORF but is predicted 
to change the C terminus residue in the cRW9 epitope from 
tryptophan to arginine ( Fig. 3 a , wild-type RHLAFKCLW, 
variant RHLAFKCLR). Because a C-terminal tryptophan is 
an anchor residue for epitopes presented by Mamu-B*17 
( 15 ), this mutation is predicted to drastically reduce binding 
to the Mamu-B*17 molecule. To test this, we performed 
competition assays using purifi ed Mamu-B*17 molecules. As 
expected, the wild-type peptide was found to be a strong 
Mamu-B*17 binder, with an affi  nity of 32 nM. Interestingly, 
the variant peptide bound Mamu-B*17 with an affi  nity of 
948 nM, representing a 97% decrease in binding capacity and 
demonstrating that the mutation drastically impairs Mamu-
B*17 binding ( Fig. 3 b ). 
 To determine if the T6913C mutation was maintained due 
to positive selection, we compared rates of synonymous and 
nonsynonymous substitutions in the ARF that encodes cRW9. 
 Figure 3.  Sequence variation in cRW9 associated with loss of 
binding and positive selection. (a) Nucleotide alignments of fi ve animals 
sequenced at time of death reveals possible escape in the cRW9 epitope. 
Animal r95003 is marked with an asterisk because this animal is  Mamu-
B*17    yet made characteristic Mamu-B*17 responses (Fig. 2 a and ex-
plained in Results and Discussion). (b) Relative binding of the cRW9 and 
the mutant peptide to the Mamu-B*17 molecule. The tryptophan, W, to 
arginine, R, mutation at the C terminus of the cRW9 peptide reduces bind-
ing to the Mamu-B*17 molecule by 97%. Binding is measured as the con-
centration of peptide at which binding of a radioactively labeled reference 
peptide is reduced by 50% (IC 50 ). (c) Means (  SE) for fi ve monkeys of the 
number of synonymous substitutions per 100 sites ( d S ) and of the number 
of nonsynonymous substitutions per 100 nonsynonymous sites ( d N ) in 
comparisons between time of death and inoculum (SIVmac239) sequences. 
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the escape variant SIV-T6913C virus ( Fig. 5 b ) but to a much 
smaller degree than wild type, resulting in a   20-fold decrease 
in vRNA ( Fig. 5 a ). This further supports that the T6913C 
mutation is an escape mutation and drastically reduces epitope 
recognition without changing the primary ORF. 
 The mechanism by which the ARF-encoding cRW9 
is translated was not determined in this study. This ARF might 
encode a novel functional protein or a variant form of a known 
protein. Several splice variants of the SIV Rev protein have 
been described ( 22 ,  23 ). However, all of these variants use the 
same splice donor site, and none is predicted to encode the 
cRW9 epitope. The most parsimonious explanation for the 
existence of cRW9 is that it is contained within an incom-
pletely spliced transcript that is exported from the nucleus 
and translated. The location of the cRW9 epitope (in the  rev 
ORF, just downstream of the only known splice donor site) 
protein function. In contrast, the ARF-encoded tryptophan in 
cRW9 is under no such constraints. 
 cRW9-specifi c CD8-TLs effectively suppress SIV replication 
in vitro 
 Because high-frequency cRW9-specifi c responses select for 
viral variants in vivo, we wanted to know whether cRW9-
specifi c CD8-TLs eff ectively inhibited viral replication in a 
functional assay ( 20 ,  21 ). We cultured a cell line from animal 
r95071 that was   99% specifi c for cRW9 by tetramer after 
4 wk. Co-culture of this line with infected primary target cells 
for 7 d resulted in a   100-fold decrease in vRNA in culture 
supernatants, as compared with cultures with no CD8-TLs 
added ( Fig. 5 a ). This suppression of viral replication was 
Mamu-B*17 restricted ( Fig. 5 b ). Additionally, the cRW9-
specifi c line suppressed replication of target cells infected with 
 Figure 4.  Viral escape in cRW9 leads to loss of recognition. (a) PBMCs from animal r95071 were tested for their ability to recognize (measured by 
spot-forming cells [SFC] per 10 6 total cells; y axis) the wild-type cRW9 and the mutant peptides at a titration of peptide concentrations (x axis). Error bars 
represent the mean   the SE for each peptide concentration. (b) Frequency of the cRW9 response, measured as a percentage of CD3  CD8  lymphocytes 
(right y axis, fi lled box symbols), from animals r98015 and r97044 was measured by staining PBMCs from various time points with Mamu-B*17 tetramers 
loaded with cRW9 peptide (x axis) to determine the frequency of the cRW9-specifi c response before, during, and after apparent escape from the cRW9 
response. The virus load of the animals is included for reference (left y axis, fi lled triangles). (c) cRW9-specifi c CD8-TLs were measured for their ability 
to recognize  Mamu-B*17  target cells infected with wild-type versus mutant SIV-T6913C. Cells were infected using the magnetofection technique 
(reference  19 ). After 24 h, recognition was assayed by ICS using IFN-  and TNF- 
 production. The far left panel shows the response of the cRW9-specifi c 
cell line to MHC-matched B cells pulsed with the cRW9 peptide, and the adjacent panel shows the response to the same B cells with no peptide pulse. 
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indicate that CD8-TL responses directed at cryptic epitopes 
might play a role in controlling SIV or HIV replication that 
is equal in all respects to responses against bona fi de proteins. 
We show that cRW9-specifi c responses are capable of driving 
viral evolution in vivo and controlling virus replication in vitro. 
These results are also of interest for vaccine design. Impor-
tantly, vaccines designed to elicit virus-specifi c CD8-TLs can 
induce such responses ( 24 ). There is no consensus on whether 
or not cryptic epitopes should be included in vaccine regi-
mens, and our data do not directly address this issue. However, 
if escape-without-consequence is a general feature of cryptic 
epitopes, they are likely to be poor vaccine immunogens. Most 
importantly, these data suggest that a complete knowledge of 
the total AIDS virus – specifi c cellular immune response will 
not be possible without accounting for such responses. 
 MATERIALS AND METHODS 
 Animals.  All animals used in this study were infected with clonal SIVmac239 
as part of previous studies, except for animal r97035 and r98015, which were 
infected with clonal SIVmac239 with escape mutations in the Mamu-A*01 
epitopes Gag 181-189 CM9 and Tat 28-35 SL8 and the Mamu-B*17 epitope 
Nef 165-173 IW9 as part of a previous study ( 25 ). All animals were housed at the 
Wisconsin National Primate Research Center (WNPRC) and cared for 
under the guidelines of the National Research Council and the University 
of Wisconsin Institutional Animal Care and Use Committee (WIACUC). 
Procedures involving animals were approved by the WIACUC. 
 Cryptic epitope prediction and MHC binding studies.  The entire 
SIVmac239 genome was conceptually translated into all three potential reading 
frames using MacVector 8 trial version. All reading frames that encode known 
viral proteins were excluded from analysis. Remaining sequences were entered 
into Web-based software (www.mamu.liai.org; reference  16 ) to predict cryp-
tic epitopes predicted to bind the Mamu-B*17 molecule with IC 50   50 nM. 
Quantitative assays to measure the binding affi  nity of peptides to purifi ed 
Mamu-B*17 molecules are based on the inhibition of binding of a radiolabeled 
standard peptide and were performed as described previously ( 15 ). 
 ELISPOT.  IFN-  ELISPOT assays were conducted as described previously 
( 26 ). Using precoated ELISpot plus kits (Mabtech), 10 5 fresh or frozen PBMCs 
were added per well along with 10   M peptide (or in serial 10-fold dilutions of 
10   M to 10 pM). Minimal optimal peptides for cRW9 and other known epi-
topes restricted by Mamu-B*17 ( 15 ), Mamu-B*08 (unpublished data), Mamu-
A*01 ( 27 ), or Mamu-A*02 ( 28 ) were used. All samples were run in duplicate 
and positive (concanavalin A) and negative (no peptide) controls were included 
in each plate. 
 MHC-I tetramer production and response testing.  Mamu-B*17 tetra-
mers were produced as described previously ( 29 ), with minor modifi cations. 
Tetramer stains were performed as described previously ( 26 ) using 5   10 5 
fresh PBMCs and 0.5   g of tetrameric complexes loaded with synthetic pep-
tides representing epitopes described in Results and Discussion. 
 vRNA sequencing.  vRNA sequencing was performed as described pre-
viously ( 17 ) but using primers designed to amplify the region surrounding 
the cRW9 epitope (6511-F, TGATCCTCGCTTGCTAACTG; 7348-R, 
CTCTTGTTCCAAGCCTGTGC). 
 Mutant virus production.  Escape variant SIV (SIV-T6913C) was created 
using site-directed mutagenesis with the following primers: forward: 
T6913C-F GCTTTTAAGTGTCTACGGGATCTATTGTAC; reverse: 
T6913C-R GTACAATAGATCCCGTAGACACTTAAAAGC. Mutagen-
esis was performed using the Quik Change kit (Stratagene) according to the 
manufacturer ’ s instructions. Viral plasmid ligation and transfection and viral 
growth and characterization were performed as described previously ( 25 ). 
indicates that it might be derived from a transcript that is ex-
ported before the removal of the intron between the 5  and 
3   rev exons. The accumulation of Rev protein might lead to 
the export of such incompletely spliced transcripts, without 
regard for the ability of these mRNAs to encode functional 
proteins. Indeed, the Rev responsive element is located within 
this intron and might explain the translation of the ARF that 
encodes cRW9. 
 Our data do not address the role that cRW9-specifi c 
CD8-TLs might play in control of SIV replication in vivo. 
They do, however, demonstrate that cRW9-specifi c responses 
are a major component of the Mamu-B*17 – restricted reper-
toire of SIV-specifi c responses. The remarkable ability of SIV to 
evade the cRW9-specifi c response without changing any func-
tional proteins suggests that the role cRW9-specifi c CD8-TLs 
play in control of AIDS virus replication might be minimal. 
However, it is diffi  cult to assess the importance of responses 
against a single epitope to overall control of a pathogen such 
as HIV or SIV. CD8-TL responses to HIV/SIV are generally 
directed at a variety of viral gene products, and in this case, a 
viral ARF. In addition, viral escape from any one CD8-TL 
response, even an immunodominant one, can be followed by 
an altering of the CD8-TL immunodominance hierarchy with 
little or no change in virus load. 
 Further experiments will be required to determine the 
mechanism and timing of cRW9 presentation. However, our 
data are important for several reasons. This is the fi rst study to 
 Figure 5.  cRW9-specifi c CD8-TLs effectively suppress SIV replica-
tion in Mamu-B*17  target cells. Quantitative PCR of vRNA on the 
fi nal day (day 7) of the assay. The ability of a cRW9-specifi c cell line de-
rived from animal r95071 to suppress wild-type or SIV-T6913C replication 
in target cells that were either Mamu-B*17  or Mamu-B*17    was mea-
sured. (a) The data is represented as fold-reduction between the wells 
with no CD8-TLs added (no CTL) and those with an E/T ratio of 1:20 
(CTL). (b) The same data as in panel a but represented as the total vRNA 
copies/ml supernatant on day 7 of the assay. Error bars represent the 
mean   the SE for each measurement. 
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